摘要
心房颤动是临床最常见的心律失常之一,同时具有较高血栓栓塞的风险,因此其致残率和致死率高,抗凝治疗能有效预防栓塞,是心房颤动患者的首要治疗。华法林是最经典的口服抗凝药物,其他抗血小板治疗及新型口服抗凝药物为心房颤动抗栓治疗提供了新的思路。而如何平衡抗栓治疗的风险与获益给临床医师带来了挑战,现就心房颤动抗栓治疗研究进展做一综述。
Atrial fibrillation is one of the commonest arrhythmia in clinical practice with high mortality,disability and morbidity due to its thromboembolic potential. Nowadays anticoagulant therapy has become the primary treatment in patients with atrial fibrillation. The most classic oral anticoagulation drug is warfarin. Others are antiplatelet therapy and novel oral anticoagulation drugs. Antithrombotic therapy is a double-edged sword. It is difficult to balance the rate of risk and benefit. This article reviews the progress of antithrombotic therapy in atrial fibrillation.
出处
《心血管病学进展》
CAS
2016年第2期142-146,共5页
Advances in Cardiovascular Diseases
关键词
心房颤动
抗凝治疗
华法林
抗血小板治疗
新型口服抗凝药
Atrial fibrillation
Anticoagulant therapy
Warfarin
Antiplatelet therapy
Non vitamin-K-antagonist oral anticoagulants
